ClinicalTrials.gg
Active, not recruitingNCT06109181Updated Nov 12, 2025

Gene Therapy for ACM Due to a PKP2 Pathogenic Variant

A Phase 1/2 interventional study of LX2020 in Arrhythmogenic Cardiomyopathy, PKP2-ACM and PKP2-ARVC, sponsored by Lexeo Therapeutics. Active, not recruiting at 5 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-11-12.

Sponsored by Lexeo Therapeutics · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 231 studies in Cardiomyopathies with a site in United States — 56 open to participants now, 69 under way, 6 of them phase 3. Cardiomyopathies · United States.

Planned enrollment
109th of 132
10 · median 42
Started
2024
with 11 others
Phase 1/2
11 of 231
2 open now
Primary completion
2026-12
later than 10 of 67 live
Registered
193rd of 231
by date
Lead sponsor
6 of 231
Lexeo Therapeutics

Among the 231 studies in Cardiomyopathies with a site in United States, this one is the 109th largest by planned enrollment of the 132 interventional ones that give a count, is one of 12 that started in 2024, is one of 11 in phase 1/2, reaches primary completion later than 10 of the 67 other live ones, and was the 193rd registered.

Cardiomyopathies

556 studies on the registry are indexed under Cardiomyopathies; 153 are open to participants now.

Browse Cardiomyopathies studies →

Open to participants now

56 of the 231 studies in Cardiomyopathies with a site in United States are open now. Recruiting first, the newest first:

51 more — sign in →

All 56 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 116 Cardiomyopathies studies recruiting now, 70 (60%) set no upper age limit and 18 (16%) stop at 75 or younger; 35 take children under 18; 22 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 231 studies in Cardiomyopathies with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 1/2, first-in-human, open-label, intravenous, dose-escalating, multicenter trial that is designed to assess the safety and tolerability of LX2020 in adult patients with PKP2-ACM

03

Conditions studied

  • Arrhythmogenic Cardiomyopathy
  • PKP2-ACM
  • PKP2-ARVC

Keywords

  • Arrhythmogenic Cardiomyopathy
  • ACM
  • Cardiomyopathy
  • ARVC
  • Arrhythmogenic Right Ventricular
  • Arrhythmogenic Right Ventricular Dysplasia
  • Genetic cardiomyopathy
  • Gene Therapy
  • PKP2 Gene
  • Plakophilin-2
  • LX2020
  • HEROIC-PKP2
  • Ventricular Arrhythmia
  • PVCs
  • Sudden Cardiac Death
  • Cardiac Arrest
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Selected Inclusion Criteria:

  • Adults with a clinical diagnosis of ACM meeting the 2010 revised Task Force Criteria (TFC)
  • Genetic testing documenting a pathogenic or likely pathogenic variant in PKP2
  • Frequent premature ventricular complexes (PVCs)
  • Implantable cardioverter-defibrillator (ICD) implantation ≥ 12 weeks prior to the pre-screening MRI
  • ≥ 40%

Selected Exclusion Criteria:

  • Evidence of variant(s) in addition to PKP2 that meets the standard criteria to be considered pathogenic or likely pathogenic for ACM
  • Other cardiac abnormalities as specified in the protocol
  • Functional Class IV at the time of consent
  • History of prior gene transfer therapy
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    LX2020

    Single ascending dose of LX2020, with a starting dose of 2.0 x10\^13 gc/kg, in multiple cohorts

    Genetic: LX2020

Interventions

  • GeneticLX2020

    LX2020 is an adeno-associated viral vector encoding the human Plakophilin-2 (PKP2) gene (AAVrh.10hPKP2)

06

What researchers measure

Primary outcomes

  1. Percentage of subjects who experienced at least 1 treatment emergent adverse event (TEAE) and/or 1 treatment emergent serious adverse event (TESAE).

    Evaluation of Safety and Tolerability of LX2020

    Time frame: 12 months

Other outcomes

  1. Selected Exploratory

    Change in the frequency of ventricular arrhythmias from baseline.

    Time frame: 12 months

07

Study locations

5 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2024 (actual). Primary completion is estimated for Dec 2026, 34 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 25, 2023
First posted
Oct 31, 2023
StartActual
Feb 29, 2024
Primary completionEst.
Dec 2026
CompletionEst.
Mar 2027
Last update
Nov 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06109181
Lead sponsor
Lexeo Therapeutics
Responsible party
Sponsor
First posted
Oct 31, 2023
Start date
Feb 29, 2024
Primary completion
Dec 2026 (estimated)
Completion
Mar 2027 (estimated)
Last update
Nov 12, 2025

Study contacts

LEXEO Clinical Trials
study director · Lexeo Therapeutics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion